Seminars in Oncology
Volume 33, Issue 6 , Pages 708-710 , December 2006

Whipsaw Cancer Treatments: The Role of Hormesis in Endocrine and Immune Therapies

  • Richmond T. Prehn

      Affiliations

    • Department of Pathology, University of Washington, Seattle, WA.
    • ,
  • David Berd

      Affiliations

    • Department of Medicine, Thomas Jefferson University, Philadelphia, PA.
    • AVAX Technologies, Inc, Philadelphia, PA.
    • Corresponding Author InformationAddress correspondence to David Berd, MD, Thomas Jefferson University, 1015 Walnut St, Suite 1024, Philadelphia, PA 19107.

References 

  1. Calabrese EJ. Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences. Environ Pollut. 2005;138:379–411
  2. Soto AM, Sonnenschein C. The two faces of janus: Sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 2001;93:1673–1675
  3. Ringertz N, Klein E, Klein G. Histopathologic studies of peritoneal implantation and lung metastasis at different stages of the gradual transformation of the MCIM mouse sarcoma into ascites form. J Natl Cancer Inst. 1957;18:173–199
  4. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:287–295
  5. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999;59:4161–4164
  6. Algarte-Genin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: Experimental paradox or clinical reality. Eur Urol. 2004;46:285–294
  7. Joly-Pharaboz MO, Ruffion A, Roch A, et al. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol. 2000;73:237–249
  8. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone naive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002;1:163–171
  9. Damber JE. Endocrine therapy for prostate cancer. Acta Oncol. 2005;44:605–609
  10. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: Results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348–2351
  11. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–536
  12. Chuu CP, Hiipakka RA, Fukuchi J, et al. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005;65:2082–2084
  13. Umekita Y, Hiipakka RA, Kokontis JM, et al. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996;93:11802–11807
  14. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81:242–251
  15. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 1998;12:941–953
  16. Zhau HY, Chang SM, Chen BQ, et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A. 1996;93:15152–15157
  17. Lopez-Otin C, Diamandis EP. Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998;19:365–396
  18. Oberfield RA, Nesto R, Cady B, et al. A multidisciplined approach for the treatment of metastatic carcinoma of the breast. Med Clin North Am. 1975;59:425–430
  19. Agnese DM, Yusuf F, Wilson JL, et al. Trends in breast cancer presentation and care according to age in a single institution. Am J Surg. 2004;188:437–439
  20. Conte PF, Gardin G, Pronzato P, et al. In vivo manipulation of human breast cancer growth by estrogens and growth hormone: Kinetic and clinical results. J Steroid Biochem Mol Biol. 1990;37:1103–1108
  21. Osipo C, Gajdos C, Cheng D, et al. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol. 2005;93:249–256
  22. Hoffman RM. Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metast Rev. 1998;17:271–277
  23. Wang Y, Xue H, Cutz JC, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005;85:1392–1404
  24. Prehn RT. Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res. 1994;54:908–914
  25. Prehn RT. The immune reaction as a stimulator of tumor growth. Science. 1972;176:170–171
  26. Horak V, Fortyn K, Hruban V, et al. Hereditary melanoblastoma in miniature pigs and its successful therapy by devitalization technique. Cell Mol Biol. 1999;45:1119–1129
  27. Noonan FP, Dudek J, Merlino G, et al. Animal models of melanoma: An HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res. 2003;16:16–25

PII: S0093-7754(06)00323-X

doi: 10.1053/j.seminoncol.2006.08.012

Seminars in Oncology
Volume 33, Issue 6 , Pages 708-710 , December 2006

Article Tools